Setting New Directions for Research in Childhood Nephrotic Syndrome: Results From a National Workshop

@article{Samuel2017SettingND,
  title={Setting New Directions for Research in Childhood Nephrotic Syndrome: Results From a National Workshop},
  author={Susan M. Samuel and Tomoko Takano and Shannon D. Scott and Genevi{\`e}ve Beno{\^i}t and Martin Bitzan and Cherry Mammen and Laurel Ryan and Catherine J Morgan},
  journal={Canadian Journal of Kidney Health and Disease},
  year={2017},
  volume={4}
}
Background: We report on the proceedings of a national workshop held in Canada with the aims to identify priorities for research in childhood nephrotic syndrome and to develop a national strategy to address these priorities. Methods: A diverse group of participants attended the meeting, including patients, family members, researchers, and health care providers. We used small group discussions to explore priorities as perceived by patients and families and by health care providers and… 

Figures and Tables from this paper

The Canadian childhood nephrotic syndrome (CHILDNEPH) study: report on mid-study feasibility, recruitment and main measures

The Canadian pediatric nephrology community established a longitudinal childhood nephrotic syndrome cohort study that confirms ongoing practice variability and will help to evaluate its impact on patient outcomes, and facilitate clinical trial implementation in nephrotsic syndrome.

Serum Protein Signatures Using Aptamer-Based Proteomics for Minimal Change Disease and Membranous Nephropathy

References

SHOWING 1-10 OF 13 REFERENCES

Childhood nephrotic syndrome—current and future therapies

This Review summarizes the currently available treatments for childhood nephrotic syndrome, and discusses selected novel pathways in podocytes that could be targeted for the development of next-generation treatments for children with this syndrome.

Substantial practice variation exists in the management of childhood nephrotic syndrome

There is substantial Canadian practice variation in NS treatment, and most notable differences between practice and Guideline recommendations were first presentation GC duration, GC-sparing agent choices in frequently relapsing and steroid-dependent patients, and biopsy practices.

Management of Childhood Onset Nephrotic Syndrome

The Children's Nephrotic Syndrome Consensus Conference was formed to systematically review the published literature and generate a children's primary nephrotic syndrome guideline for use in educational, therapeutic, and research venues.

Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of nephrotic syndrome in children.

  • S. SamuelM. Bitzan N. Muirhead
  • Medicine
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2014
The KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guideline for management of glomerulonephritis was recently released. The Canadian Society of Nephrology convened a working

Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future.

  • R. MaasJ. DeegensJ. Wetzels
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2014
The history of the search for permeability factors is described, the pitfalls that are likely responsible for the lack of success are discussed and criteria that should be used in future studies when evaluating candidate permeable factors are proposed.

Nephrotic syndrome in childhood

A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment

2 months of initial prednisolone therapy for steroid-sensitive nephrotic syndrome, despite less prednisOLone exposure, is not inferior to 6 months ofInitial therapy in terms of time to onset of frequently relapsing neph rotic syndrome.

Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome.

Extending initial prednisolone treatment from 3 to 6 months without increasing cumulative dose did not benefit clinical outcome in children with nephrotic syndrome, and previous findings indicating that prolonged treatment regimens reduce relapses most likely resulted from increased cumulative dose rather than the treatment duration.

Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome.

Extending initial prednisolone treatment from 3 to 6 months does not influence the course of illness in children with nephrotic syndrome, and these findings have implications for guiding the duration of therapy of nephrotsic syndrome.

Corticosteroid therapy for steroid-sensitive nephrotic syndrome in children: dose or duration?

Idiopathic nephrotic syndrome is the most common primary glomerular disease among children and causes substantial morbidity because it typically runs a relapsing course punctuated with prolonged periods of corticosteroids and other immunosuppressive medication.